Neumora Therapeutics announced that its antidepressant candidate, navacaprant, did not meet the primary endpoint in a Phase 3 study for major depressive disorder.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Antidepressant fails in final stage study
